Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Recipient : MEDUNIK CANADA
Deal Size : Inapplicable
Deal Type : Inapplicable
Médunik Canada's Ruzurgi® Now Available to Canadian Lambert-Eaton Myasthenic Syndrome Patients
Details : Médunik Canada has retained the services of Innomar, a leading specialty pharmaceutical service and patient support program provider, for the distribution of Ruzurgi® and management of its UnikAccess Patient Support Program.
Product Name : Ruzurgi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2020
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Recipient : MEDUNIK CANADA
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amifampridine
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Recipient : Jeffrey A. Cohen
Deal Size : Inapplicable
Deal Type : Inapplicable
Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2014
Lead Product(s) : Amifampridine
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Recipient : Jeffrey A. Cohen
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diaminopyridine
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Undisclosed
Recipient : Oregon Health and Science University
Deal Size : Inapplicable
Deal Type : Inapplicable
3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 17, 2013
Lead Product(s) : Diaminopyridine
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Undisclosed
Recipient : Oregon Health and Science University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amifampridine
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 19, 2012
Lead Product(s) : Amifampridine
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
